Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor
argenx
Study ID
NCT04777734
Status
Available

Conditions

  • CIDP
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Efgartigimod PH20 SC — BIOLOGICAL
    Subcutaneous administration of Efgartigimod PH20 (via vial or prefilled syringe)

Study Details

The aim of the Pre-Approval Access program is to provide efgartigimod PH20 SC treatment to patients with CIDP who are ineligible to participate in a clinical study and have unmet medical need despite available treatment options. The program will continue until the patient discontinues treatment or until the reimbursement process for CIDP concludes, whichever comes first.

Key Dates

Status verified
Mar 2026

Central Contacts

Related Studies